Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
67
Frequently Asked Questions
What is Market Cap of Inozyme Pharma Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Inozyme Pharma Inc market cap is $258.25M.
What is the 52-week high for Inozyme Pharma Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Inozyme Pharma Inc 52 week high is $6.24 as of October 25, 2025.
What is the 52-week low for Inozyme Pharma Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Inozyme Pharma Inc 52 week low is $0.721 as of October 25, 2025.
What is the PE ratio of Inozyme Pharma Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Inozyme Pharma Inc’s P/E ratio is -2.38.
What is the Price-to-Book ratio of Inozyme Pharma Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Inozyme Pharma Inc P/B ratio is 8.1100.
What is the 50-day moving average of Inozyme Pharma Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Inozyme Pharma Inc 50-day moving average is $3.28.
